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Abstract Short interfering RNAs (siRNAs) have proved to be
a useful tool in studying gene function in plants, invertebrates
and mammalian systems. Here we report the use of siRNAs for
targeting the zebra¢sh dystrophin gene. This study demonstrates
the e⁄cacy of siRNA-based gene silencing in this vertebrate
model species, and illustrates the potential of this approach
for determining the roles of multiple protein products expressed
by a single gene during the early stages of development. In
addition this study illustrates the usefulness of zebra¢sh as a
model for muscle disease, and highlights the potential of siRNA-
based gene targeting for disease analysis in this model organism.
& 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Gene silencing via double-stranded RNAs (dsRNAs) has
had a signi¢cant impact on the ability to suppress gene ex-
pression in a wide range of species encompassing mice, human
cells, plants, Drosophila melanogaster, Caenorhabditis elegans
and yeast [1,2]. To date, some studies of gene silencing in the
zebra¢sh, which is an emerging model for disease analysis,
have shown non-speci¢c e¡ects on gene expression following
the microinjection of long (s 30 bp) dsRNAs into embryos
[3]. This outcome probably re£ects signi¢cant di¡erences in
how vertebrates react to long dsRNA compared to inverte-
brates. To combat this problem, gene silencing approaches in
mammalian systems are now based on using short interfering
RNAs (siRNAs) to avoid generalised non-speci¢c e¡ects due
to the induction of interferon and the activation of interferon-
response genes by long dsRNA [4]. Currently, the use of si-
RNAs for gene silencing in the zebra¢sh has not been docu-
mented, although a recent report has shown the e¡ectiveness
of siRNA gene silencing in rainbow trout embryos [5].
We decided to investigate the use of siRNAs in targeting
the zebra¢sh Duchenne muscular dystrophy (dmd) gene. This
approach was considered to o¡er potential in dissecting the
roles of multiple proteins expressed by this gene. Importantly,
the zebra¢sh o¡ers signi¢cant advantages compared to other
model systems in the analysis of muscle-related diseases and
early developmental e¡ects [6].
In humans, the Duchenne muscular dystrophy gene contains
eight promoters and expresses multiple transcripts with vary-
ing tissue speci¢city and developmental regulation [7,8]. These
transcripts, comprising alternatively spliced variants, encode
proteins ranging in size from 427 kDa to 71 kDa (Fig. 1). The
full-length transcript expressed in muscle gives rise to a 427
kDa dystrophin protein (Dp427m) that links cytoskeletal ac-
tin to the extracellular matrix via the sarcolemmal dystrophin-
associated glycoprotein complex (DGC) [8,9]. The role of
Dp427m ranges from muscle stabilisation during contraction
to localisation of signalling molecules [10,11]. The functional
signi¢cance of those transcripts of the dystrophin gene encod-
ing other 427 kDa proteins, and the smaller proteins (Fig. 1)
that are expressed in the retina and central nervous system
during development, remains unclear [11]. Importantly, the
zebra¢sh dmd gene expresses a number of isoforms that are
similar in size to those found in human tissues [12]. In addi-
tion, zebra¢sh dystrophin (Dp427m) and the DGC are found
in the sarcolemma with strong localisation to transverse my-
osepta [12^15].
We describe here the use of siRNAs directed against the
carboxy-terminal coding region of the zebra¢sh dystrophin
gene to e¡ect restricted temporal targeting of the family of
dystrophin gene transcripts. This study involved assessing the
impact of siRNAs on the expression and localisation of dys-
trophin and selected members of the DGC, as well as muscle
architecture, in order to determine the temporal window of
e¡ect and speci¢city.
2. Materials and methods
2.1. siRNA design
Potential siRNA target sites in the zebra¢sh were determined using
Oligoengine (DNA Engine), and Qiagen siRNA design (Qiagen) pro-
grammes. Synthesised siRNA duplexes were purchased from Xeragon
in the case of the zebra¢sh dystrophin gene, and Dharmacon (Dallas,
TX, USA) in the case of the siRNA against the green £uorescent
protein (catalogue number D-001300-01-05; see Table 1). Stock con-
centrations of 50 WM were injected into single cell zebra¢sh embryos
with an average injection volume of 0.3 nl.
2.2. Quantitative real-time polymerase chain reaction (PCR)
Zebra¢sh embryos were collected (10^20 embryos per time point),
and RNA was extracted using Trizol (Invitrogen) and further puri¢ed
using RNeasy columns (Qiagen). 1 Wg total RNA from each extrac-
tion was reverse transcribed using Superscript III (Invitrogen) and
random primers in a 20 Wl reaction volume according to the manu-
facturer’s instructions. cDNA samples were diluted 1:5 before use in
quantitative PCR (Q-PCR) assays, and templates were pipetted in a
minimum volume of 4 Wl per 20 Wl Q-PCR to minimise variation.
Q-PCRs were performed using an Applied Biosystems model
7900HT platform and a mixture of Taqman probe and Sybr green
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dye chemistries. All reactions (20 Wl) were performed in triplicate.
Taqman universal mastermix (Applied Biosystems) was used with
Taqman probes and a standard PCR mix using Platinum Taq DNA
polymerase (Invitrogen) supplemented with 0.2 Wl/20 Wl reaction of a
1:2000 dilution of Sybr green dye (Molecular Probes) in the case of
Sybr assays. All primers and probes were designed to conform to a
universal cycling programme using the Primer Express programme
(Applied Biosystems). Three control genes were used in all experi-
ments (GAPDH, L-actin, 18S rRNA; the primers and probe for the
latter were supplied by Applied Biosystems). The two least variable
control genes were determined for each experiment and normalisation
factors were calculated based on the geometric mean of these two
genes using the program geNorm [16]. Relative expression was calcu-
lated using a modi¢ed comparative CT method with correction for
di¡erent ampli¢cation e⁄ciencies [17]. See Table 1 for sequences of
primers and probes.
2.3. Light microscopy
Images of zebra¢sh embryos were recorded using di¡erential inter-
ference contrast (DIC) optics on a Zeiss Axiovert S100 microscope
and a Zeiss Axiocam digital camera.
2.4. Wholemount immunohistochemistry
Embryos were manually dechorionated and ¢xed in methanol over-
night at 320‡C then washed in phosphate-bu¡ered saline (PBS), in-
cubated 10 min in 1UPBS with 0.1% Triton X-100, washed in PTWs
(1UPBS, 0.1% Tween 20, 0.3% saponin) and blocked for at least 1 h
in PBTs (1UPBS; 1% bovine serum albumin, 0.1% Tween 20, 0.3%
saponin). Following blocking, embryos were incubated with monoclo-
nal antibodies against: dystrophin (MANCHO 12) (http://www.ne-
wi.ac.uk/morrisge/mabs.htm#DMD), L-sarcoglycan (NCL-b-SARC)
and L-dystroglycan (NCL-b-DG) (Novocastra Laboratories, http://
www.novocastra.co.uk/md.htm), at 1:3 dilution in PBTs for at least
3 h at room temperature. The primary antibody was removed, then
samples were washed six times in PTWs and were again blocked for at
least 1 h in PBTs before incubation with secondary antibody. The
secondary antibody, goat anti-mouse IgG lissamine-rhodamine con-
jugate (Jackson ImmunoResearch, USA), was pre-adsorbed against a
crude zebra¢sh protein extract in PBTs before use then diluted at 1:50
in PBTs and incubated with samples for at least 1 h at room temper-
ature. Antibody was removed and samples were washed with six
PTWs washes then resuspended in 90% glycerol/10% PBS and rocked
gently for 2 h prior to mounting. The rhodamine label was detected
by scanning confocal imaging of embryos mounted in 1% low melting
point agarose using a Leica TCS SP2 laser scanning confocal micro-
scope [15].
2.5. Electron microscopy
Embryos were manually dechorionated and ¢xed overnight at 4‡C
in 2% paraformaldehyde, 2% glutaraldehyde in 0.1 M sodium caco-
dylate bu¡er pH 7.2 (SCB). After three washes in 1USCB samples
were post¢xed in 1% osmium tetroxide for 1 h. Embryos were washed
twice in 0.5USCB, dehydrated in a graded ethanol series, and em-
bedded in EM bed 812 resin (Electron Microscopy Sciences, USA).
Ultrathin (60 nm) longitudinal sections were cut, counter-stained with
2% aqueous uranyl acetate for 20 min then stained with Reynolds lead
citrate for 3 min and visualised using a Philips Tecnai 12 transmission
electron microscope (FEI, The Netherlands) [18].
3. Results and discussion
siRNAs were designed against carboxy-terminal exons 53
and 68 of the zebra¢sh dmd gene, and each was introduced
into zebra¢sh embryos by microinjection. The e¡ect of si-
RNA-68 was initially assessed by Q-PCR of zebra¢sh dystro-
phin gene transcripts through the ampli¢cation of the exon
targeted by this siRNA. This assessment involved normalisa-
tion against two reference genes (L-actin and 18S rRNA). Fig.
1 shows a temporal reduction in the level of the dystrophin
family of transcripts, while there was no inhibitory e¡ect of
siRNA-68 on the relative expression level of the L-sarcoglycan
gene transcript. The protein encoded by this transcript is a
member of the DGC complex to which Dp427m binds. Mi-
croarray-based studies of Duchenne muscular dystrophy pa-
tient muscle have shown that the levels of transcripts encoding
the sarcoglycans are not decreased despite reduced levels of
Dp427m transcripts in these patients, possibly due to non-
sense-mediated decay [19]. As an additional control, siRNA
against the transcript of the green £uorescent protein (siRNA-
GFP) was also microinjected into zebra¢sh embryos; this si-
RNA was used in the studies described by Novina et al. [20].
Q-PCR analysis showed no signi¢cant changes in the level of
the dystrophin family of transcripts between injected and un-
injected embryos at 12 h post fertilisation (hpf) and 24 hpf
(see Supplementary Fig. 1).
Confocal microscopy of wholemount zebra¢sh embryos
showed that by 24 h of development, dystrophin, L-sarcogly-
can and L-dystroglycan are localised to myosepta (Fig. 2). In
contrast, siRNA-68 and siRNA-53 injected embryos showed
delayed localisation of dystrophin and L-sarcoglycan (28 hpf),
with no apparent delay in terms of L-dystroglycan (24 hpf,
Fig. 2). Interestingly, zebra¢sh treated with a morpholino tar-
geted to the translational start site of Dp427m [21], and the
sapje zebra¢sh mutant that carries a nonsense mutation in
exon 4 of the dmd gene [22] exhibit a lack of localisation of
dystrophin and members of the sarcoglycan sub-complex of
the DGC at zebra¢sh myosepta.
Electron micrographs of zebra¢sh muscle showed disorgan-
Table 1
Sequences of siRNAs, primers and probes
Description Type Sequence (5P to 3P)
Zebra¢sh dmd gene siRNA target sequences siRNA-53 AAGTTTCGCACAGCGTTGAAG
siRNA-68 AAACCGGAGTTAGAGGCTTCA
Green £uorescent protein siRNA target sequence siRNA-GFP GGCTACGTCCAGGAGCGCACC
PCR primers for the zebra¢sh dmd gene transcript (Sybr green assays) Exon 53 FOR AAAAGGGTGGAGCCTCTCATTAAG
REV TTAGAAAGTTGCTTGACATCTGCAT
Exon 68 FOR GCTGCTTTCAGTTCGCCAAT
REV TCGACTGAGGTTCTAAACGCATC
PCR primers for the zebra¢sh L-sarcoglycan gene transcript FOR GGGTCGCAAAGGCATCTTC
REV ACTGTCCATATCACCAGAGTTATAATGAG
PCR primers and probe for the zebra¢sh L-actin gene transcript PCR primers FOR CGAGCTGTCTTCCCATCCA
REV TCACCAACGTAGCTGTCTTTCTG
Taqman probe CCCATACCAACCATGACACCCTGATGT
PCR primers and probe for the zebra¢sh GAPDH gene transcript PCR primers FOR CGCTGGCATCTCCCTCAA
REV TCAGCAACACGATGGCTGTAG
Taqman probe CCAAATTCGTTGTCATACCAGGAGATGAGCT
Zebra¢sh sequences were identi¢ed from the zebra¢sh genome and whole genome shotgun traces (http://www.sanger.ac.uk/Projects/D_rerio).
FEBS 28129 1-3-04 Cyaan Magenta Geel Zwart
A. Dodd et al./FEBS Letters 561 (2004) 89^9390
ised sarcomeres in siRNA-68 and siRNA-53 injected embryos
at 36 hpf (Fig. 2). Light microscopic DIC images of siRNA-53
and siRNA-68 injected embryos showed the delayed develop-
ment of myotubes, with disruption of the characteristic chev-
ron shape of myosepta yielding U-shaped somites (Fig. 3). In
addition, the larvae of siRNA-68 injected embryos exhibited
signi¢cant curvature and reduced motility with an impaired
touch response (data not shown). These features are shared to
varying extents with those found in zebra¢sh due to morpho-
lino-based translational knockdown of Dp427m [21] and dys-
troglycan [18]. The sapje mutant is less a¡ected with the
detachment of muscle ¢bres from myosepta, which is accom-
panied by the collapse of sarcomeres [22].
Taken together, our data support the use of siRNAs for
gene targeting in the zebra¢sh, albeit in a brief temporal man-
ner, and thus demonstrate the e¡ective use of gene silencing
via siRNAs in the last major model organism where this has
not been successfully demonstrated previously. The work de-
scribed here supports the use of siRNAs as a tool to achieve
targeted loss of function in a vertebrate model system in
which multiple promoters complicate the expression of the
targeted gene.
Our conclusion of the speci¢city of gene silencing in zebra-
¢sh via siRNAs rests on several observations. First, the func-
tional readout of siRNA-68 is at the transcript level, thus
negating the possibility of a micro-RNA role for siRNA-68.
Secondly, titration experiments have been undertaken to
achieve a minimum e¡ective dose of siRNA-68; four-fold
higher doses yielded more severe phenotypes (data not
shown). Thirdly, siRNA-68 injected embryos provided a sim-
ilar readout to those injected with siRNA-53 in terms of
muscle phenotype. Finally, the data mirror to a large extent
the confocal and muscle morphological analyses reported for
morpholino-based translational knockdown of the zebra¢sh
dystroglycan and dystrophin genes [18,21], and the sapje ze-
bra¢sh mutant [22].
The work described here adheres to the precepts of what
constitutes the best controls in gene silencing by RNAi, albeit
without the virtue of rescue controls [23]. We have deliber-
ately not used mismatched siRNAs because of their limited
usefulness and unanticipated e¡ects [23]. We have assessed
speci¢city through Q-PCR analysis that provides evidence
supporting a transcriptional e¡ect on the gene we have tar-
geted, with no evidence of non-speci¢c reduction of transcript
levels based on the use of three unrelated reference genes. The
immunohistochemical and ultrastructural data, and the com-
parison with morpholino-treated and mutant zebra¢sh re-
ported in the literature, serve to support the transcriptional
Fig. 1. Dystrophin gene transcript family and e¡ect of siRNAs on relative transcript levels. A: The family of transcripts expressed by the hu-
man dystrophin gene. The organisation of the transcripts is depicted schematically. The arrows indicate transcription start sites for dystrophin
isoforms expressed in lymphoid, cortical, muscle and Purkinje cells (Dp427 isoforms), and the smaller isoforms expressed in the retina (Dp260)
and the central nervous system (Dp140-Dp71). B,C: Quantitative PCR analysis of transcripts expressed from the dystrophin and L-sarcoglycan
genes, respectively; (a) control and (b) siRNA-68 injected. The fold change in transcript level is based arbitrarily on the lowest transcript level
detected in the samples measured in each experiment (24 h siRNA injected embryos and 12 h control embryos in B and C, respectively). Verti-
cal bars indicate standard deviations.
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data. Finally, the lack of any detectable dmd gene transcrip-
tional e¡ects using siRNA-GFP as a negative control under-
scores the conclusion of siRNA speci¢city.
The outcome of microinjecting siRNAs into zebra¢sh em-
bryos o¡ers similarities to the use of pre-mRNA splice site
targeting by morpholinos [24]. The distinction to be drawn
here, however, is that the creation of transgenic zebra¢sh lines
expressing siRNAs in a tissue-speci¢c or regulated manner
could o¡er the means of e¡ecting controlled changes in gene
expression in order to ablate as well as to rescue. In this way,
siRNA expression cassettes in zebra¢sh have the potential to
overcome the limitations of relying on transient unregulated
gene targeting, while opening up the possibility of using the
Fig. 2. Histochemical and ultrastructural analysis of siRNA injected zebra¢sh embryos. A: Immunolocalisation of DGC proteins to the myo-
septa in zebra¢sh embryos at 24 hpf and 28 hpf. Embryos were incubated with anti-dystrophin (dys), anti-L-sarcoglycan (L-sar) or anti-L-dys-
troglycan (L-dys) monoclonal antibodies (scale bar equals 200 Wm). At 24 hpf the injected embryos are negative for dystrophin and L-sarcogly-
can, whereas L-dystroglycan was detected. Control embryos were all positive for these peptides. At 28 hpf injected embryos begin to show
localisation of dystrophin and L-sarcoglycan peptides at their myosepta. B: Ultrastructural analysis of ultrathin longitudinal sections of 36 hpf
zebra¢sh embryos injected with siRNAs showing disruption of myosepta (double arrowheads) and ¢bre organisation compared to control em-
bryos (scale bars equal 500 nm). Detailed examination of ¢bre reveals that the z-lines (single arrowheads) and other structures are irregular in
injected embryos compared to controls.
6
Fig. 3. Light micrographs of siRNA injected embryos. Control em-
bryos exhibit chevron-shaped myosepta at 24 hpf and the nuclei of
myoblasts (single arrowhead) are visible in the somites where myo-
tubes are formed by fusion of myoblasts. Myotubes can be observed
maturing to striated ¢bres throughout the somites in 28 hpf unin-
jected embryos (double arrowhead). In contrast, nuclei of condens-
ing myotubes are less evident in siRNA injected embryos at 24 hpf
but are observed at greater frequency at 28 hpf and are particularly
visible about the midline of the embryo (scale bar equals 100 Wm).
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zebra¢sh for functional vertebrate gene analysis in a disease
context, allowing in vivo targeting of multiple transcripts,
whether encoded by one gene or several genes.
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